241 related articles for article (PubMed ID: 35831362)
1. Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.
Dai L; Mugaanyi J; Cai X; Lu C; Lu C
Sci Rep; 2022 Jul; 12(1):11944. PubMed ID: 35831362
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
3. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
4. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
[TBL] [Abstract][Full Text] [Related]
5. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32579175
[TBL] [Abstract][Full Text] [Related]
6. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
8. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells.
Wang Y; Yang Y; Zhao Z; Sun H; Luo D; Huttad L; Zhang B; Han B
BMC Cancer; 2022 Apr; 22(1):379. PubMed ID: 35397536
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
10. Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma.
Dong Y; Tian J; Yan B; Lv K; Li J; Fu D
Pathol Oncol Res; 2021; 27():1609822. PubMed ID: 34290570
[TBL] [Abstract][Full Text] [Related]
11. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases.
Mao M; Ling H; Lin Y; Chen Y; Xu B; Zheng R
Front Genet; 2021; 12():702102. PubMed ID: 34335699
[TBL] [Abstract][Full Text] [Related]
12. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
13. A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma.
Zhang X; Li X; Xie J; Zhu Q; Yuan Y
J Oncol; 2022; 2022():8909631. PubMed ID: 35342420
[TBL] [Abstract][Full Text] [Related]
14. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a RARRES3-based prognostic signature related to the specific immune microenvironment of pancreatic cancer.
Sun Y; Wang X; Yao L; He R; Man C; Fan Y
Front Oncol; 2024; 14():1246308. PubMed ID: 38375157
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
[No Abstract] [Full Text] [Related]
17.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
18. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study.
Wu G; Deng Z; Jin Z; Wang J; Xu B; Zeng J; Peng M; Wen Z; Guo Y
Biomed Res Int; 2020; 2020():1346045. PubMed ID: 32596278
[TBL] [Abstract][Full Text] [Related]
19. Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma.
Wu Z; Huang X; Cai M; Huang P; Guan Z
Aging (Albany NY); 2022 Jan; 14(2):869-891. PubMed ID: 35077391
[TBL] [Abstract][Full Text] [Related]
20. Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma.
Su K; Peng Y; Yu H
Dis Markers; 2022; 2022():9141117. PubMed ID: 35677632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]